Status:
COMPLETED
Bioavailability and Effectiveness of Transdermally Administered Morphine
Lead Sponsor:
Alberta Health services
Collaborating Sponsors:
Tom Baker Cancer Centre
Conditions:
Cancer
Pain
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
Patients will participate in two arms of the trial, one in which morphine will be administered transdermally, and, after a 3 day wash out period, one in which morphine will be administered subcutaneou...
Detailed Description
Patients will participate in two arms of the trial, one in which morphine will be administered transdermally, and, after a 3 day wash out period, one in which morphine will be administered subcutaneou...
Eligibility Criteria
Inclusion
- Chronic cancer pain
- Minimum baseline pain of 3/10
- No change in medications over 3 days prior to study period
- Ability to give informed consent
- Willingness to undergo repeated blood sampling
Exclusion
- Use of morphine or codeine in 3 days prior to study
- Known sensitivity to morphine
- Prior anaphylactic reaction to any opioid
- Clinically significant anemia
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2008
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00125684
Start Date
July 1 2003
End Date
July 1 2008
Last Update
January 19 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2